ArticleJournal of cosmetic dermatology2025
Anti-Inflammatory Efficacy of a Functional Shampoo Mixed With 0.063% Artemether for Seborrheic Dermatitis.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-Inflammatory Efficacy of a Functional Shampoo Mixed With 0.063% Artemether for Seborrheic Dermatitis.Journal of cosmetic dermatology · 2025Article
- Anti-Inflammatory Efficacy of a Functional Shampoo Mixed With 0.063% Artemether for Seborrheic Dermatitis.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSeborrheic dermatitis (SD) is a chronic inflammatory skin disease. Artemisinin and its derivatives have been applied in the treatment of various skin diseases, but they have not yet been used in the treatment of SD.
aimsTo evaluate the therapeutic effect and anti-inflammatory effect of 0.063% artemether shampoo on SD through a guinea pig model.
methodFifty SD-induced guinea pigs were randomized into control, ketoconazole (2%), matrix, and artemether (0.063%) groups (n = 10/group). Treatments were applied twice weekly for 2 weeks. Erythema and scaling were scored pre-/posttreatment. Lesional IL-1β, IL-8, IL-17, NF-κB, and histamine H1 levels were quantified via immunohistochemistry.
resultsArtemether group demonstrated lower scores versus control and matrix group (both p < 0.05), comparable to ketoconazole group (p > 0.05). Artemether group reduced IL-1β, IL-8, NF-κB, and histamine H1 vs. control group(p < 0.05), with IL-8 suppression exceeding ketoconazole and matrix group (p < 0.05; p < 0.001). No intergroup differences in IL-17 were observed (p > 0.05).
conclusionThe 0.063% artemether shampoo has comparable clinical efficacy to the 2% ketoconazole shampoo in the treatment of SD, and may exhibit stronger anti-inflammatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.